Bristol's Maxipime antibiotic will launch in second quarter; recommended dose ranges from .5 g to 2 g b.i.d.
BRISTOL-MYERS SQUIBB MAXIPIME TO BE INTRODUCED IN SECOND QUARTER, the company indicated Jan. 24. The intravenous cephalosporin antibiotic cefepime (NDA 50-679) was approved Jan. 18 for uncomplicated and complicated urinary tract infections, uncomplicated skin and skin structure infections and pneumonia ("The Pink Sheet" Jan. 22, T&G-1).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth